- Home
- EXPI vs MNKD Comparison
EXPI vs MNKD Comparison
Compare EXPI & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EXPI | MNKD |
|---|---|---|
| Founded | 2008 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 877.0M |
| IPO Year | 2010 | 2004 |
Fundamental Metrics
Financial Performance| Metric | EXPI | MNKD |
|---|---|---|
| Price | $6.74 | $3.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $9.75 | $8.69 |
| AVG Volume (30 Days) | 798.2K | ★ 5.1M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.18% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $500,147,681.00 | $348,966,000.00 |
| Revenue This Year | $6.26 | $35.81 |
| Revenue Next Year | $5.50 | $11.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 220.39 | 22.23 |
| 52 Week Low | $5.66 | $2.23 |
| 52 Week High | $12.23 | $6.51 |
Technical Indicators
Market Signals| Indicator | EXPI | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 60.03 | 72.27 |
| Support Level | $5.68 | $3.39 |
| Resistance Level | $6.87 | $6.08 |
| Average True Range (ATR) | 0.23 | 0.22 |
| MACD | 0.04 | 0.12 |
| Stochastic Oscillator | 81.56 | 56.18 |
Price Performance
Historical ComparisonAbout EXPI eXp World Holdings Inc.
eXp World Holdings Inc is a cloud-based residential real estate company. The company owns and operates a cloud-based real estate brokerage and a technology platform business that develops and uses immersive technologies that help businesses increase their effectiveness and reduce costs from operating in traditional brick-and-mortar office spaces. Its business categories include Real Estate Brokerage, Technology Products and Services, Title, Escrow, Settlement Services, and Mortgage Brokerage Services.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.